Sara Shahhosseini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sara Shahhosseini has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Mir Hosseini
Medical doctor, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Danial Soltani
Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Maryam Zare
Department of Biology, Faculty of Sciences, Payame Noor University, Tehran, Iran
1 shared publication - Nima Komeili
Undergraduate Student, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
1 shared publication - Razieh Razmi
Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Reza Biglarifard
Faculty of Pharmacy, Damghan Branch, Islamic Azad University, Damghan, Iran
1 shared publication
Latest Publications
- Open Access
- 25 December 2023
- Published by Rovedar in Journal of Lab Animal Research
- Vol. 2 (6) , 86-99
Advances in Nanotechnology for Enhanced Leukemia Therapy: A Systematic Review of In Vivo Studies
Background/Objective: Leukemia, a heterogeneous group of blood cancers, can present a significant clinical challenge due to its varying subtypes and complexity. The application of nanotechnology has the potential to revolutionize the treatment of leukemia. Based on in vivo studies, this systematic review provides an accurate and current assessment of nanotechnology therapeutic advances in leukemia treatment. Methods: The present systematic review focused on in vivo studies investigating nanotechnology's therapeutic potential for leukemia treatment. Comprehensive searches were conducted across leading databases, including PubMed, Scopus, and Google Scholar, to identify relevant publications. Selection criteria encompassed studies that employed animal models to assess nanotechnology effects on leukemia progression. Data extracted from selected articles were rigorously analyzed. This review included studies published between 2010 and 2022. Results: Based on the inclusion criteria, 24 relevant studies were identified. According to the findings of this review, nanotechnology has made substantial progress in the treatment of leukemia, as demonstrated by in vivo studies. Advanced nanoparticle-based drug delivery systems, precision gene therapies, and targeted therapeutic approaches have consistently exhibited superior outcomes in treating various leukemia subtypes in animal models. These compelling results emphasize the transformative potential of nanotechnology for leukemia therapy. Conclusion: In conclusion, the meticulous analyses of the in vivo studies underscore the role that nanotechnology plays in the advancement of the treatment of leukemia. Nanotechnology has demonstrated efficacy in preclinical models, indicating that it can be translated into clinical applications, offering new avenues for treating leukemia and reinforcing its position as an innovative therapeutic approach.
- 25 December 2023
- Published by Rovedar in Journal of Lab Animal Research
- Vol. 2 (6) , 86-99
Open AccessAdvances in Nanotechnology for Enhanced Leukemia Therapy: A Systematic Review of In Vivo Studies
Background/Objective: Leukemia, a heterogeneous group of blood cancers, can present a significant clinical challenge due to its varying subtypes and complexity. The application of nanotechnology has the potential to revolutionize the treatment of leukemia. Based on in vivo studies, this systematic review provides an accurate and current assessment of nanotechnology therapeutic advances in leukemia treatment. Methods: The present systematic review focused on in vivo studies investigating nanotechnology's therapeutic potential for leukemia treatment. Comprehensive searches were conducted across leading databases, including PubMed, Scopus, and Google Scholar, to identify relevant publications. Selection criteria encompassed studies that employed animal models to assess nanotechnology effects on leukemia progression. Data extracted from selected articles were rigorously analyzed. This review included studies published between 2010 and 2022. Results: Based on the inclusion criteria, 24 relevant studies were identified. According to the findings of this review, nanotechnology has made substantial progress in the treatment of leukemia, as demonstrated by in vivo studies. Advanced nanoparticle-based drug delivery systems, precision gene therapies, and targeted therapeutic approaches have consistently exhibited superior outcomes in treating various leukemia subtypes in animal models. These compelling results emphasize the transformative potential of nanotechnology for leukemia therapy. Conclusion: In conclusion, the meticulous analyses of the in vivo studies underscore the role that nanotechnology plays in the advancement of the treatment of leukemia. Nanotechnology has demonstrated efficacy in preclinical models, indicating that it can be translated into clinical applications, offering new avenues for treating leukemia and reinforcing its position as an innovative therapeutic approach.
- Open Access
- 1 February 2023
- Published by Apex Publishing in Iranian South Medical Journal
- Vol. 25 (6) , 489-504
Association of rs2787094 in ADAM33 and rs11650354 in TBX21 Gene Polymorphisms with Asthma in ian Patients
Background: Asthma is a common inflammatory disease of the airways which is characterized by variable and recurrent symptomes. The disease causes airways inflamtion and hyperresponsiveness, reversible airways obstruction and airway deformity and accomponied with symptoms including shortness of breath, cough and wheezing in patients. Environmental and genetic factor such as gene ...
- 1 February 2023
- Published by Apex Publishing in Iranian South Medical Journal
- Vol. 25 (6) , 489-504
Open AccessAssociation of rs2787094 in ADAM33 and rs11650354 in TBX21 Gene Polymorphisms with Asthma in ian Patients
Background: Asthma is a common inflammatory disease of the airways which is characterized by variable and recurrent symptomes. The disease causes airways inflamtion and hyperresponsiveness, reversible airways obstruction and airway deformity and accomponied with symptoms including shortness of breath, cough and wheezing in patients. Environmental and genetic factor such as gene ...